Legal Reform Proposals Arising from the Food and Drug Administration Generic Drug Scandal: Clinical Research and Regulatory Affairs: Vol 9, No 1

Views

CrossRef citations to date

Altmetric

Abstract

This study was undertaken with the help of generic drug manufacturers to learn their perceived reasons for delay in Abbreviated New Drug Application (ANDA) by the Food and Drug Administration (FDA). The research resulted into proposing legal reforms in existing laws to prevent ANDA scandals in the future.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Legal Reform Proposals Arising from the Food and Drug Administration Generic Drug Scandal

Information for

Open access

Opportunities

Help and information

Legal Reform Proposals Arising from the Food and Drug Administration Generic Drug Scandal

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature